• Publications
  • Influence
Spatially Restricted G Protein-coupled Receptor Activity via Divergent Endocytic Compartments*
Background: Following ligand-induced internalization, GPCRs are sorted by diverse receptor motifs and protein interactions. Results: Distinct GPCRs are targeted to a pre-early endosome compartmentExpand
  • 74
  • 7
Functional Characterization of Vasopressin Type 2 Receptor Substitutions (R137H/C/L) Leading to Nephrogenic Diabetes Insipidus and Nephrogenic Syndrome of Inappropriate Antidiuresis: Implications for
Substitution of arginine-137 of the vasopressin type 2 receptor (V2R) for histidine (R137H-V2R) leads to nephrogenic diabetes insipidus (NDI), whereas substitution of the same residue to cysteine orExpand
  • 59
  • 5
  • PDF
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
DCs are critical cellular targets of PD-L1 blockade in cancer treatment. Checkpoint musical chairs Anti–PD-1 or PD-L1 antibodies can reinvigorate antitumor immunity in a subset of patients withExpand
  • 48
  • 5
Engineered Protein Connectivity to Actin Mimics PDZ-dependent Recycling of G Protein-coupled Receptors but Not Its Regulation by Hrs*
Many G protein-coupled receptors (GPCRs) recycle after agonist-induced endocytosis by a sequence-dependent mechanism, which is distinct from default membrane flow and remains poorly understood.Expand
  • 15
  • 3
Temporal reprogramming of calcium signalling via crosstalk of gonadotrophin receptors that associate as functionally asymmetric heteromers
Signal crosstalk between distinct G protein-coupled receptors (GPCRs) is one mechanism that underlies pleiotropic signalling. Such crosstalk is also pertinent for GPCRs activated by gonadotrophicExpand
  • 27
  • 2
  • PDF
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Tumor-targeted 4-1BB agonists provide costimulation as combination partners for cancer immunotherapies in solid and hematological tumors. For the love of 4-1BB Antibodies activating the 4-1BBExpand
  • 63
  • 2
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Purpose: Despite promising clinical activity, T-cell–engaging therapies including T-cell bispecific antibodies (TCB) are associated with severe side effects requiring the use of step-up-dosing (SUD)Expand
  • 47
  • 2
Running Title : Signalling and trafficking of NDI and NSIAD V 2 R mutations
Moulay D. Rochdi, Gabriel A. Vargas, Eric Carpentier, Geneviève Oligny-Longpré, Stanford Chen, Abraham Kovoor, Stephen E. Gitelman, Stephen M. Rosenthal, Mark von Zastrow and Michel Bouvier* InstitutExpand